Plain-English translation of NCT04687631 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding cetuximab or bevacizumab to a chemotherapy combination called mFOLFOXIRI can help shrink colorectal cancer that has spread to the liver. The goal is to shrink the cancer enough so that surgery becomes possible to remove the remaining disease. You would be randomly assigned to receive one of these two treatment combinations.
When colorectal cancer spreads to the liver and cannot be surgically removed right away, doctors need the strongest possible chemotherapy to shrink the tumors. This trial is trying to figure out which combination of this medication with chemotherapy works better to make surgery possible and improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy infusions every 2 weeks for at least 6 months, combined with either cetuximab or bevacizumab depending on which group you're assigned to. Every 8 weeks, you would have CT or MRI scans to see how well the treatment is working. If your tumors shrink enough to become removable, you would have surgery, and your total treatment time would total 6 months including any chemotherapy after surgery.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China